nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—DNMT1—breast cancer	0.185	0.363	CbGaD
Procainamide—SCN10A—breast cancer	0.115	0.226	CbGaD
Procainamide—ACHE—breast cancer	0.109	0.215	CbGaD
Procainamide—SLC22A3—Melphalan—breast cancer	0.0943	0.411	CbGbCtD
Procainamide—BCHE—breast cancer	0.0643	0.126	CbGaD
Procainamide—CYP2D6—breast cancer	0.0353	0.0694	CbGaD
Procainamide—ACHE—Irinotecan—breast cancer	0.0329	0.143	CbGbCtD
Procainamide—SLC22A3—Irinotecan—breast cancer	0.0319	0.139	CbGbCtD
Procainamide—BCHE—Irinotecan—breast cancer	0.0198	0.0863	CbGbCtD
Procainamide—SLC22A2—Vinblastine—breast cancer	0.0168	0.0732	CbGbCtD
Procainamide—CYP2D6—Idarubicin—breast cancer	0.014	0.061	CbGbCtD
Procainamide—CYP2D6—Vinorelbine—breast cancer	0.00684	0.0298	CbGbCtD
Procainamide—CYP2D6—Tamoxifen—breast cancer	0.00617	0.0269	CbGbCtD
Procainamide—CYP2D6—Vinblastine—breast cancer	0.00421	0.0184	CbGbCtD
Procainamide—CYP2D6—Doxorubicin—breast cancer	0.00259	0.0113	CbGbCtD
Procainamide—DNMT1—mammary gland—breast cancer	0.0014	0.0367	CbGeAlD
Procainamide—DNMT1—nipple—breast cancer	0.00116	0.0303	CbGeAlD
Procainamide—DNMT1—embryo—breast cancer	0.000954	0.025	CbGeAlD
Procainamide—DNMT1—Vinblastine—Vinorelbine—breast cancer	0.000888	0.564	CbGdCrCtD
Procainamide—SLC22A4—mammary gland—breast cancer	0.000866	0.0227	CbGeAlD
Procainamide—SCN7A—adipose tissue—breast cancer	0.000819	0.0215	CbGeAlD
Procainamide—DNMT1—epithelium—breast cancer	0.000778	0.0204	CbGeAlD
Procainamide—SCN7A—female reproductive system—breast cancer	0.000753	0.0198	CbGeAlD
Procainamide—DNMT1—skin of body—breast cancer	0.00074	0.0194	CbGeAlD
Procainamide—SCN7A—adrenal gland—breast cancer	0.000735	0.0193	CbGeAlD
Procainamide—DNMT1—endometrium—breast cancer	0.000698	0.0183	CbGeAlD
Procainamide—SCN7A—female gonad—breast cancer	0.000685	0.018	CbGeAlD
Procainamide—SLC22A3—nipple—breast cancer	0.000652	0.0171	CbGeAlD
Procainamide—SCN9A—pituitary gland—breast cancer	0.000644	0.0169	CbGeAlD
Procainamide—DNMT1—uterus—breast cancer	0.000643	0.0169	CbGeAlD
Procainamide—SCN9A—adipose tissue—breast cancer	0.000641	0.0168	CbGeAlD
Procainamide—SCN7A—endocrine gland—breast cancer	0.000637	0.0167	CbGeAlD
Procainamide—DNMT1—pituitary gland—breast cancer	0.000632	0.0166	CbGeAlD
Procainamide—DNMT1—adipose tissue—breast cancer	0.000629	0.0165	CbGeAlD
Procainamide—DNMT1—female reproductive system—breast cancer	0.000578	0.0152	CbGeAlD
Procainamide—SCN9A—adrenal gland—breast cancer	0.000575	0.0151	CbGeAlD
Procainamide—SCN4A—pituitary gland—breast cancer	0.000575	0.0151	CbGeAlD
Procainamide—SLC22A5—mammary gland—breast cancer	0.000573	0.015	CbGeAlD
Procainamide—SCN4A—adipose tissue—breast cancer	0.000572	0.015	CbGeAlD
Procainamide—SCN8A—endocrine gland—breast cancer	0.000568	0.0149	CbGeAlD
Procainamide—DNMT1—adrenal gland—breast cancer	0.000564	0.0148	CbGeAlD
Procainamide—DNMT1—bone marrow—breast cancer	0.000546	0.0143	CbGeAlD
Procainamide—SLC22A3—embryo—breast cancer	0.000538	0.0141	CbGeAlD
Procainamide—DNMT1—female gonad—breast cancer	0.000526	0.0138	CbGeAlD
Procainamide—SCN4A—adrenal gland—breast cancer	0.000513	0.0135	CbGeAlD
Procainamide—SCN2A—pituitary gland—breast cancer	0.000509	0.0133	CbGeAlD
Procainamide—SCN10A—pituitary gland—breast cancer	0.00049	0.0129	CbGeAlD
Procainamide—DNMT1—endocrine gland—breast cancer	0.000489	0.0128	CbGeAlD
Procainamide—SLC22A5—nipple—breast cancer	0.000474	0.0124	CbGeAlD
Procainamide—BCHE—nipple—breast cancer	0.000462	0.0121	CbGeAlD
Procainamide—ACHE—adrenal gland—breast cancer	0.000458	0.012	CbGeAlD
Procainamide—SCN3A—pituitary gland—breast cancer	0.000447	0.0117	CbGeAlD
Procainamide—SCN3A—adipose tissue—breast cancer	0.000445	0.0117	CbGeAlD
Procainamide—SCN7A—lymph node—breast cancer	0.00044	0.0116	CbGeAlD
Procainamide—SLC22A4—endometrium—breast cancer	0.000432	0.0113	CbGeAlD
Procainamide—SCN3A—female reproductive system—breast cancer	0.000409	0.0107	CbGeAlD
Procainamide—SCN3A—adrenal gland—breast cancer	0.000399	0.0105	CbGeAlD
Procainamide—SCN2A—endocrine gland—breast cancer	0.000394	0.0103	CbGeAlD
Procainamide—SLC22A3—endometrium—breast cancer	0.000394	0.0103	CbGeAlD
Procainamide—SLC22A4—pituitary gland—breast cancer	0.000391	0.0103	CbGeAlD
Procainamide—SLC22A4—adipose tissue—breast cancer	0.00039	0.0102	CbGeAlD
Procainamide—SCN3A—bone marrow—breast cancer	0.000386	0.0101	CbGeAlD
Procainamide—SCN10A—endocrine gland—breast cancer	0.00038	0.00997	CbGeAlD
Procainamide—SLC22A1—adipose tissue—breast cancer	0.000371	0.00974	CbGeAlD
Procainamide—SLC22A4—female reproductive system—breast cancer	0.000358	0.0094	CbGeAlD
Procainamide—SLC22A3—adipose tissue—breast cancer	0.000355	0.00931	CbGeAlD
Procainamide—SLC22A4—adrenal gland—breast cancer	0.00035	0.00917	CbGeAlD
Procainamide—SCN9A—lymph node—breast cancer	0.000345	0.00905	CbGeAlD
Procainamide—DNMT1—Betamethasone—Fluoxymesterone—breast cancer	0.000343	0.218	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Fluoxymesterone—breast cancer	0.000343	0.218	CbGdCrCtD
Procainamide—DNMT1—lymph node—breast cancer	0.000338	0.00888	CbGeAlD
Procainamide—SLC22A4—bone marrow—breast cancer	0.000338	0.00888	CbGeAlD
Procainamide—SLC22A3—female reproductive system—breast cancer	0.000326	0.00856	CbGeAlD
Procainamide—SLC22A3—adrenal gland—breast cancer	0.000318	0.00835	CbGeAlD
Procainamide—Sunitinib—STK11—breast cancer	0.000312	0.0609	CrCbGaD
Procainamide—SLC22A5—skin of body—breast cancer	0.000304	0.00797	CbGeAlD
Procainamide—SLC22A3—female gonad—breast cancer	0.000297	0.00779	CbGeAlD
Procainamide—Lucanthone—TOP2A—breast cancer	0.000296	0.0578	CrCbGaD
Procainamide—BCHE—skin of body—breast cancer	0.000296	0.00776	CbGeAlD
Procainamide—CHRM2—endocrine gland—breast cancer	0.000294	0.00771	CbGeAlD
Procainamide—SLC22A1—endocrine gland—breast cancer	0.000289	0.00758	CbGeAlD
Procainamide—SLC22A5—endometrium—breast cancer	0.000286	0.00751	CbGeAlD
Procainamide—BCHE—endometrium—breast cancer	0.000279	0.00731	CbGeAlD
Procainamide—SLC22A3—endocrine gland—breast cancer	0.000276	0.00724	CbGeAlD
Procainamide—ACHE—lymph node—breast cancer	0.000275	0.00721	CbGeAlD
Procainamide—SCN10A—lymph node—breast cancer	0.000263	0.00689	CbGeAlD
Procainamide—Proparacaine—SCN10A—breast cancer	0.000259	0.0506	CrCbGaD
Procainamide—SLC22A5—pituitary gland—breast cancer	0.000259	0.0068	CbGeAlD
Procainamide—SLC22A5—adipose tissue—breast cancer	0.000258	0.00677	CbGeAlD
Procainamide—BCHE—uterus—breast cancer	0.000257	0.00674	CbGeAlD
Procainamide—BCHE—pituitary gland—breast cancer	0.000252	0.00662	CbGeAlD
Procainamide—BCHE—adipose tissue—breast cancer	0.000251	0.00659	CbGeAlD
Procainamide—SCN3A—lymph node—breast cancer	0.000239	0.00628	CbGeAlD
Procainamide—Oxybuprocaine—SCN10A—breast cancer	0.000237	0.0463	CrCbGaD
Procainamide—SLC22A5—female reproductive system—breast cancer	0.000237	0.00622	CbGeAlD
Procainamide—SLC22A5—adrenal gland—breast cancer	0.000231	0.00607	CbGeAlD
Procainamide—BCHE—female reproductive system—breast cancer	0.000231	0.00606	CbGeAlD
Procainamide—BCHE—adrenal gland—breast cancer	0.000225	0.00591	CbGeAlD
Procainamide—Chloroprocaine—SCN10A—breast cancer	0.00022	0.043	CrCbGaD
Procainamide—BCHE—bone marrow—breast cancer	0.000218	0.00572	CbGeAlD
Procainamide—SLC22A5—female gonad—breast cancer	0.000216	0.00566	CbGeAlD
Procainamide—Cinchocaine—SCN10A—breast cancer	0.00021	0.041	CrCbGaD
Procainamide—Procaine—SCN10A—breast cancer	0.00021	0.041	CrCbGaD
Procainamide—SLC22A4—lymph node—breast cancer	0.00021	0.0055	CbGeAlD
Procainamide—Sunitinib—CHEK2—breast cancer	0.000201	0.0393	CrCbGaD
Procainamide—BCHE—endocrine gland—breast cancer	0.000195	0.00513	CbGeAlD
Procainamide—SLC22A3—lymph node—breast cancer	0.000191	0.00501	CbGeAlD
Procainamide—Metoclopramide—CYP17A1—breast cancer	0.000189	0.0369	CrCbGaD
Procainamide—Sunitinib—FGFR1—breast cancer	0.000188	0.0366	CrCbGaD
Procainamide—Sunitinib—FGFR2—breast cancer	0.000188	0.0366	CrCbGaD
Procainamide—Sunitinib—ALK—breast cancer	0.000179	0.035	CrCbGaD
Procainamide—Sunitinib—FLT1—breast cancer	0.000179	0.035	CrCbGaD
Procainamide—Sunitinib—CSF1R—breast cancer	0.00017	0.0332	CrCbGaD
Procainamide—Aminohippurate—SLCO1B1—breast cancer	0.000169	0.033	CrCbGaD
Procainamide—Benzocaine—SCN10A—breast cancer	0.000167	0.0326	CrCbGaD
Procainamide—CYP2D6—female reproductive system—breast cancer	0.000153	0.00401	CbGeAlD
Procainamide—Probenecid—ABCC1—breast cancer	0.000142	0.0276	CrCbGaD
Procainamide—Aminohippurate—ABCC1—breast cancer	0.00014	0.0273	CrCbGaD
Procainamide—CYP2D6—female gonad—breast cancer	0.000139	0.00365	CbGeAlD
Procainamide—SLC22A5—lymph node—breast cancer	0.000139	0.00364	CbGeAlD
Procainamide—Lidocaine—SCN10A—breast cancer	0.000136	0.0266	CrCbGaD
Procainamide—BCHE—lymph node—breast cancer	0.000135	0.00354	CbGeAlD
Procainamide—Oxybuprocaine—BCHE—breast cancer	0.000133	0.0259	CrCbGaD
Procainamide—CYP2D6—endocrine gland—breast cancer	0.000129	0.0034	CbGeAlD
Procainamide—Chloroprocaine—BCHE—breast cancer	0.000123	0.0241	CrCbGaD
Procainamide—Cinchocaine—BCHE—breast cancer	0.000118	0.023	CrCbGaD
Procainamide—Procaine—BCHE—breast cancer	0.000118	0.023	CrCbGaD
Procainamide—Sunitinib—KDR—breast cancer	0.000112	0.0219	CrCbGaD
Procainamide—Sunitinib—KIT—breast cancer	0.000106	0.0207	CrCbGaD
Procainamide—Lidocaine—EGFR—breast cancer	9.83e-05	0.0192	CrCbGaD
Procainamide—Hypotension—Gemcitabine—breast cancer	8.49e-05	0.000777	CcSEcCtD
Procainamide—Flushing—Docetaxel—breast cancer	8.43e-05	0.000771	CcSEcCtD
Procainamide—Cardiac disorder—Docetaxel—breast cancer	8.43e-05	0.000771	CcSEcCtD
Procainamide—Cardiac arrest—Epirubicin—breast cancer	8.42e-05	0.00077	CcSEcCtD
Procainamide—Vomiting—Tamoxifen—breast cancer	8.41e-05	0.00077	CcSEcCtD
Procainamide—Malaise—Paclitaxel—breast cancer	8.41e-05	0.00077	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—breast cancer	8.39e-05	0.000768	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—breast cancer	8.36e-05	0.000765	CcSEcCtD
Procainamide—Dizziness—Goserelin—breast cancer	8.35e-05	0.000764	CcSEcCtD
Procainamide—Hypotension—Fluorouracil—breast cancer	8.35e-05	0.000764	CcSEcCtD
Procainamide—Hypersensitivity—Vinorelbine—breast cancer	8.34e-05	0.000763	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Gemcitabine—breast cancer	8.28e-05	0.000758	CcSEcCtD
Procainamide—Vomiting—Melphalan—breast cancer	8.23e-05	0.000754	CcSEcCtD
Procainamide—Moclobemide—CYP2D6—breast cancer	8.17e-05	0.0159	CrCbGaD
Procainamide—Cardiac disorder—Capecitabine—breast cancer	8.16e-05	0.000747	CcSEcCtD
Procainamide—Flushing—Capecitabine—breast cancer	8.16e-05	0.000747	CcSEcCtD
Procainamide—Chills—Docetaxel—breast cancer	8.15e-05	0.000746	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Fluorouracil—breast cancer	8.14e-05	0.000745	CcSEcCtD
Procainamide—Asthenia—Vinorelbine—breast cancer	8.12e-05	0.000743	CcSEcCtD
Procainamide—Decreased appetite—Mitoxantrone—breast cancer	8.11e-05	0.000742	CcSEcCtD
Procainamide—Decreased appetite—Irinotecan—breast cancer	8.11e-05	0.000742	CcSEcCtD
Procainamide—Eosinophilia—Methotrexate—breast cancer	8.1e-05	0.000741	CcSEcCtD
Procainamide—Nausea—Vinblastine—breast cancer	8.09e-05	0.00074	CcSEcCtD
Procainamide—Abdominal pain upper—Epirubicin—breast cancer	8.09e-05	0.00074	CcSEcCtD
Procainamide—Convulsion—Paclitaxel—breast cancer	8.08e-05	0.000739	CcSEcCtD
Procainamide—Vomiting—Goserelin—breast cancer	8.03e-05	0.000735	CcSEcCtD
Procainamide—Pruritus—Vinorelbine—breast cancer	8.01e-05	0.000733	CcSEcCtD
Procainamide—Hypersensitivity—Thiotepa—breast cancer	7.96e-05	0.000729	CcSEcCtD
Procainamide—Myalgia—Paclitaxel—breast cancer	7.94e-05	0.000727	CcSEcCtD
Procainamide—Arthralgia—Paclitaxel—breast cancer	7.94e-05	0.000727	CcSEcCtD
Procainamide—Decreased appetite—Gemcitabine—breast cancer	7.9e-05	0.000723	CcSEcCtD
Procainamide—Chills—Capecitabine—breast cancer	7.89e-05	0.000722	CcSEcCtD
Procainamide—Nausea—Tamoxifen—breast cancer	7.86e-05	0.000719	CcSEcCtD
Procainamide—Discomfort—Paclitaxel—breast cancer	7.84e-05	0.000718	CcSEcCtD
Procainamide—Abdominal discomfort—Methotrexate—breast cancer	7.84e-05	0.000717	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—breast cancer	7.79e-05	0.000713	CcSEcCtD
Procainamide—Decreased appetite—Fluorouracil—breast cancer	7.77e-05	0.000711	CcSEcCtD
Procainamide—Asthenia—Thiotepa—breast cancer	7.75e-05	0.000709	CcSEcCtD
Procainamide—Diarrhoea—Vinorelbine—breast cancer	7.74e-05	0.000708	CcSEcCtD
Procainamide—Dysgeusia—Docetaxel—breast cancer	7.74e-05	0.000708	CcSEcCtD
Procainamide—Nausea—Melphalan—breast cancer	7.69e-05	0.000704	CcSEcCtD
Procainamide—Feeling abnormal—Mitoxantrone—breast cancer	7.69e-05	0.000704	CcSEcCtD
Procainamide—Feeling abnormal—Irinotecan—breast cancer	7.69e-05	0.000704	CcSEcCtD
Procainamide—Confusional state—Paclitaxel—breast cancer	7.67e-05	0.000702	CcSEcCtD
Procainamide—Neutropenia—Methotrexate—breast cancer	7.65e-05	0.0007	CcSEcCtD
Procainamide—Pruritus—Thiotepa—breast cancer	7.65e-05	0.0007	CcSEcCtD
Procainamide—Gastrointestinal pain—Mitoxantrone—breast cancer	7.63e-05	0.000698	CcSEcCtD
Procainamide—Gastrointestinal pain—Irinotecan—breast cancer	7.63e-05	0.000698	CcSEcCtD
Procainamide—Eosinophilia—Epirubicin—breast cancer	7.58e-05	0.000693	CcSEcCtD
Procainamide—Nausea—Goserelin—breast cancer	7.5e-05	0.000687	CcSEcCtD
Procainamide—Dysgeusia—Capecitabine—breast cancer	7.49e-05	0.000686	CcSEcCtD
Procainamide—Feeling abnormal—Gemcitabine—breast cancer	7.49e-05	0.000685	CcSEcCtD
Procainamide—Shock—Paclitaxel—breast cancer	7.49e-05	0.000685	CcSEcCtD
Procainamide—Dizziness—Vinorelbine—breast cancer	7.48e-05	0.000685	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—breast cancer	7.48e-05	0.000685	CcSEcCtD
Procainamide—Thrombocytopenia—Paclitaxel—breast cancer	7.45e-05	0.000682	CcSEcCtD
Procainamide—Urticaria—Mitoxantrone—breast cancer	7.41e-05	0.000678	CcSEcCtD
Procainamide—Diarrhoea—Thiotepa—breast cancer	7.39e-05	0.000677	CcSEcCtD
Procainamide—Body temperature increased—Irinotecan—breast cancer	7.38e-05	0.000675	CcSEcCtD
Procainamide—Abdominal pain—Irinotecan—breast cancer	7.38e-05	0.000675	CcSEcCtD
Procainamide—Body temperature increased—Mitoxantrone—breast cancer	7.38e-05	0.000675	CcSEcCtD
Procainamide—Abdominal pain—Mitoxantrone—breast cancer	7.38e-05	0.000675	CcSEcCtD
Procainamide—Feeling abnormal—Fluorouracil—breast cancer	7.37e-05	0.000674	CcSEcCtD
Procainamide—Depression—Methotrexate—breast cancer	7.27e-05	0.000665	CcSEcCtD
Procainamide—Anorexia—Paclitaxel—breast cancer	7.25e-05	0.000664	CcSEcCtD
Procainamide—Vomiting—Vinorelbine—breast cancer	7.19e-05	0.000658	CcSEcCtD
Procainamide—Body temperature increased—Gemcitabine—breast cancer	7.19e-05	0.000658	CcSEcCtD
Procainamide—Renal failure—Methotrexate—breast cancer	7.17e-05	0.000656	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—breast cancer	7.15e-05	0.000655	CcSEcCtD
Procainamide—Dizziness—Thiotepa—breast cancer	7.15e-05	0.000654	CcSEcCtD
Procainamide—Hypotension—Paclitaxel—breast cancer	7.11e-05	0.000651	CcSEcCtD
Procainamide—Ill-defined disorder—Capecitabine—breast cancer	7.1e-05	0.00065	CcSEcCtD
Procainamide—Urticaria—Fluorouracil—breast cancer	7.1e-05	0.00065	CcSEcCtD
Procainamide—Body temperature increased—Fluorouracil—breast cancer	7.07e-05	0.000647	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—breast cancer	7.01e-05	0.000641	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Paclitaxel—breast cancer	6.93e-05	0.000635	CcSEcCtD
Procainamide—Malaise—Capecitabine—breast cancer	6.9e-05	0.000632	CcSEcCtD
Procainamide—Hypersensitivity—Irinotecan—breast cancer	6.88e-05	0.000629	CcSEcCtD
Procainamide—Hypersensitivity—Mitoxantrone—breast cancer	6.88e-05	0.000629	CcSEcCtD
Procainamide—Vomiting—Thiotepa—breast cancer	6.87e-05	0.000629	CcSEcCtD
Procainamide—Convulsion—Docetaxel—breast cancer	6.85e-05	0.000627	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—breast cancer	6.8e-05	0.000623	CcSEcCtD
Procainamide—Arthralgia—Docetaxel—breast cancer	6.73e-05	0.000616	CcSEcCtD
Procainamide—Myalgia—Docetaxel—breast cancer	6.73e-05	0.000616	CcSEcCtD
Procainamide—Nausea—Vinorelbine—breast cancer	6.72e-05	0.000615	CcSEcCtD
Procainamide—Renal failure—Epirubicin—breast cancer	6.71e-05	0.000614	CcSEcCtD
Procainamide—Asthenia—Irinotecan—breast cancer	6.7e-05	0.000613	CcSEcCtD
Procainamide—Asthenia—Mitoxantrone—breast cancer	6.7e-05	0.000613	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—breast cancer	6.62e-05	0.000606	CcSEcCtD
Procainamide—Decreased appetite—Paclitaxel—breast cancer	6.62e-05	0.000605	CcSEcCtD
Procainamide—Hypersensitivity—Fluorouracil—breast cancer	6.58e-05	0.000603	CcSEcCtD
Procainamide—Asthenia—Gemcitabine—breast cancer	6.52e-05	0.000597	CcSEcCtD
Procainamide—Myalgia—Capecitabine—breast cancer	6.52e-05	0.000596	CcSEcCtD
Procainamide—Arthralgia—Capecitabine—breast cancer	6.52e-05	0.000596	CcSEcCtD
Procainamide—Confusional state—Docetaxel—breast cancer	6.5e-05	0.000595	CcSEcCtD
Procainamide—Discomfort—Capecitabine—breast cancer	6.44e-05	0.000589	CcSEcCtD
Procainamide—Pruritus—Gemcitabine—breast cancer	6.43e-05	0.000589	CcSEcCtD
Procainamide—Nausea—Thiotepa—breast cancer	6.42e-05	0.000587	CcSEcCtD
Procainamide—Diarrhoea—Mitoxantrone—breast cancer	6.38e-05	0.000584	CcSEcCtD
Procainamide—Diarrhoea—Irinotecan—breast cancer	6.38e-05	0.000584	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—breast cancer	6.37e-05	0.000583	CcSEcCtD
Procainamide—Shock—Docetaxel—breast cancer	6.35e-05	0.000581	CcSEcCtD
Procainamide—Pruritus—Fluorouracil—breast cancer	6.32e-05	0.000579	CcSEcCtD
Procainamide—Thrombocytopenia—Docetaxel—breast cancer	6.32e-05	0.000578	CcSEcCtD
Procainamide—Confusional state—Capecitabine—breast cancer	6.3e-05	0.000576	CcSEcCtD
Procainamide—Feeling abnormal—Paclitaxel—breast cancer	6.27e-05	0.000574	CcSEcCtD
Procainamide—Bradycardia—Epirubicin—breast cancer	6.23e-05	0.000571	CcSEcCtD
Procainamide—Gastrointestinal pain—Paclitaxel—breast cancer	6.22e-05	0.00057	CcSEcCtD
Procainamide—Diarrhoea—Gemcitabine—breast cancer	6.22e-05	0.000569	CcSEcCtD
Procainamide—Renal failure—Doxorubicin—breast cancer	6.21e-05	0.000568	CcSEcCtD
Procainamide—Dizziness—Irinotecan—breast cancer	6.17e-05	0.000565	CcSEcCtD
Procainamide—Anorexia—Docetaxel—breast cancer	6.15e-05	0.000563	CcSEcCtD
Procainamide—Shock—Capecitabine—breast cancer	6.14e-05	0.000562	CcSEcCtD
Procainamide—Diarrhoea—Fluorouracil—breast cancer	6.12e-05	0.00056	CcSEcCtD
Procainamide—Thrombocytopenia—Capecitabine—breast cancer	6.12e-05	0.00056	CcSEcCtD
Procainamide—Cardiac disorder—Methotrexate—breast cancer	6.07e-05	0.000556	CcSEcCtD
Procainamide—Urticaria—Paclitaxel—breast cancer	6.05e-05	0.000553	CcSEcCtD
Procainamide—Hypotension—Docetaxel—breast cancer	6.03e-05	0.000552	CcSEcCtD
Procainamide—Abdominal pain—Paclitaxel—breast cancer	6.02e-05	0.000551	CcSEcCtD
Procainamide—Body temperature increased—Paclitaxel—breast cancer	6.02e-05	0.000551	CcSEcCtD
Procainamide—Anorexia—Capecitabine—breast cancer	5.95e-05	0.000545	CcSEcCtD
Procainamide—Vomiting—Mitoxantrone—breast cancer	5.93e-05	0.000543	CcSEcCtD
Procainamide—Vomiting—Irinotecan—breast cancer	5.93e-05	0.000543	CcSEcCtD
Procainamide—Dizziness—Fluorouracil—breast cancer	5.91e-05	0.000541	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—breast cancer	5.89e-05	0.000539	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Docetaxel—breast cancer	5.88e-05	0.000538	CcSEcCtD
Procainamide—Sunitinib—ABCG2—breast cancer	5.88e-05	0.0115	CrCbGaD
Procainamide—Chills—Methotrexate—breast cancer	5.87e-05	0.000537	CcSEcCtD
Procainamide—Hypotension—Capecitabine—breast cancer	5.84e-05	0.000534	CcSEcCtD
Procainamide—Vomiting—Gemcitabine—breast cancer	5.78e-05	0.000529	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—breast cancer	5.77e-05	0.000528	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Capecitabine—breast cancer	5.69e-05	0.000521	CcSEcCtD
Procainamide—Flushing—Epirubicin—breast cancer	5.68e-05	0.00052	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—breast cancer	5.68e-05	0.00052	CcSEcCtD
Procainamide—Vomiting—Fluorouracil—breast cancer	5.68e-05	0.00052	CcSEcCtD
Procainamide—Decreased appetite—Docetaxel—breast cancer	5.61e-05	0.000513	CcSEcCtD
Procainamide—Hypersensitivity—Paclitaxel—breast cancer	5.61e-05	0.000513	CcSEcCtD
Procainamide—Dysgeusia—Methotrexate—breast cancer	5.58e-05	0.000511	CcSEcCtD
Procainamide—Nausea—Irinotecan—breast cancer	5.54e-05	0.000507	CcSEcCtD
Procainamide—Nausea—Mitoxantrone—breast cancer	5.54e-05	0.000507	CcSEcCtD
Procainamide—Chills—Epirubicin—breast cancer	5.5e-05	0.000503	CcSEcCtD
Procainamide—Asthenia—Paclitaxel—breast cancer	5.46e-05	0.0005	CcSEcCtD
Procainamide—Decreased appetite—Capecitabine—breast cancer	5.43e-05	0.000497	CcSEcCtD
Procainamide—Nausea—Gemcitabine—breast cancer	5.4e-05	0.000494	CcSEcCtD
Procainamide—Pruritus—Paclitaxel—breast cancer	5.38e-05	0.000493	CcSEcCtD
Procainamide—Feeling abnormal—Docetaxel—breast cancer	5.32e-05	0.000486	CcSEcCtD
Procainamide—Nausea—Fluorouracil—breast cancer	5.31e-05	0.000486	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—breast cancer	5.29e-05	0.000484	CcSEcCtD
Procainamide—Gastrointestinal pain—Docetaxel—breast cancer	5.28e-05	0.000483	CcSEcCtD
Procainamide—Metoclopramide—CYP2D6—breast cancer	5.27e-05	0.0103	CrCbGaD
Procainamide—Cardiac disorder—Doxorubicin—breast cancer	5.26e-05	0.000481	CcSEcCtD
Procainamide—Flushing—Doxorubicin—breast cancer	5.26e-05	0.000481	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—breast cancer	5.22e-05	0.000478	CcSEcCtD
Procainamide—Diarrhoea—Paclitaxel—breast cancer	5.21e-05	0.000477	CcSEcCtD
Procainamide—Feeling abnormal—Capecitabine—breast cancer	5.15e-05	0.000471	CcSEcCtD
Procainamide—Malaise—Methotrexate—breast cancer	5.14e-05	0.00047	CcSEcCtD
Procainamide—Gastrointestinal pain—Capecitabine—breast cancer	5.11e-05	0.000467	CcSEcCtD
Procainamide—Body temperature increased—Docetaxel—breast cancer	5.1e-05	0.000467	CcSEcCtD
Procainamide—Abdominal pain—Docetaxel—breast cancer	5.1e-05	0.000467	CcSEcCtD
Procainamide—Chills—Doxorubicin—breast cancer	5.08e-05	0.000465	CcSEcCtD
Procainamide—Dizziness—Paclitaxel—breast cancer	5.03e-05	0.000461	CcSEcCtD
Procainamide—Urticaria—Capecitabine—breast cancer	4.96e-05	0.000454	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—breast cancer	4.95e-05	0.000453	CcSEcCtD
Procainamide—Body temperature increased—Capecitabine—breast cancer	4.94e-05	0.000452	CcSEcCtD
Procainamide—Abdominal pain—Capecitabine—breast cancer	4.94e-05	0.000452	CcSEcCtD
Procainamide—Convulsion—Methotrexate—breast cancer	4.94e-05	0.000452	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—breast cancer	4.85e-05	0.000444	CcSEcCtD
Procainamide—Myalgia—Methotrexate—breast cancer	4.85e-05	0.000444	CcSEcCtD
Procainamide—Vomiting—Paclitaxel—breast cancer	4.84e-05	0.000443	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—breast cancer	4.83e-05	0.000442	CcSEcCtD
Procainamide—Malaise—Epirubicin—breast cancer	4.81e-05	0.00044	CcSEcCtD
Procainamide—Discomfort—Methotrexate—breast cancer	4.79e-05	0.000439	CcSEcCtD
Procainamide—Hypersensitivity—Docetaxel—breast cancer	4.75e-05	0.000435	CcSEcCtD
Procainamide—Confusional state—Methotrexate—breast cancer	4.69e-05	0.000429	CcSEcCtD
Procainamide—Asthenia—Docetaxel—breast cancer	4.63e-05	0.000424	CcSEcCtD
Procainamide—Convulsion—Epirubicin—breast cancer	4.62e-05	0.000423	CcSEcCtD
Procainamide—Hypersensitivity—Capecitabine—breast cancer	4.6e-05	0.000421	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—breast cancer	4.58e-05	0.000419	CcSEcCtD
Procainamide—Pruritus—Docetaxel—breast cancer	4.56e-05	0.000418	CcSEcCtD
Procainamide—Thrombocytopenia—Methotrexate—breast cancer	4.55e-05	0.000417	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—breast cancer	4.54e-05	0.000415	CcSEcCtD
Procainamide—Myalgia—Epirubicin—breast cancer	4.54e-05	0.000415	CcSEcCtD
Procainamide—Nausea—Paclitaxel—breast cancer	4.52e-05	0.000414	CcSEcCtD
Procainamide—Discomfort—Epirubicin—breast cancer	4.48e-05	0.00041	CcSEcCtD
Procainamide—Asthenia—Capecitabine—breast cancer	4.48e-05	0.00041	CcSEcCtD
Procainamide—Malaise—Doxorubicin—breast cancer	4.45e-05	0.000407	CcSEcCtD
Procainamide—Anorexia—Methotrexate—breast cancer	4.43e-05	0.000406	CcSEcCtD
Procainamide—Pruritus—Capecitabine—breast cancer	4.42e-05	0.000404	CcSEcCtD
Procainamide—Diarrhoea—Docetaxel—breast cancer	4.41e-05	0.000404	CcSEcCtD
Procainamide—Confusional state—Epirubicin—breast cancer	4.39e-05	0.000401	CcSEcCtD
Procainamide—Hypotension—Methotrexate—breast cancer	4.34e-05	0.000398	CcSEcCtD
Procainamide—Shock—Epirubicin—breast cancer	4.28e-05	0.000392	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—breast cancer	4.27e-05	0.000391	CcSEcCtD
Procainamide—Diarrhoea—Capecitabine—breast cancer	4.27e-05	0.000391	CcSEcCtD
Procainamide—Dizziness—Docetaxel—breast cancer	4.27e-05	0.00039	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—breast cancer	4.26e-05	0.00039	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—breast cancer	4.24e-05	0.000388	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—breast cancer	4.2e-05	0.000384	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—breast cancer	4.2e-05	0.000384	CcSEcCtD
Procainamide—Lidocaine—CYP2D6—breast cancer	4.18e-05	0.00816	CrCbGaD
Procainamide—Discomfort—Doxorubicin—breast cancer	4.15e-05	0.00038	CcSEcCtD
Procainamide—Anorexia—Epirubicin—breast cancer	4.15e-05	0.00038	CcSEcCtD
Procainamide—Dizziness—Capecitabine—breast cancer	4.13e-05	0.000378	CcSEcCtD
Procainamide—Vomiting—Docetaxel—breast cancer	4.1e-05	0.000375	CcSEcCtD
Procainamide—Hypotension—Epirubicin—breast cancer	4.07e-05	0.000372	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—breast cancer	4.06e-05	0.000371	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—breast cancer	4.04e-05	0.00037	CcSEcCtD
Procainamide—Vomiting—Capecitabine—breast cancer	3.97e-05	0.000363	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—breast cancer	3.96e-05	0.000363	CcSEcCtD
Procainamide—Shock—Doxorubicin—breast cancer	3.96e-05	0.000362	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—breast cancer	3.94e-05	0.000361	CcSEcCtD
Procainamide—Anorexia—Doxorubicin—breast cancer	3.84e-05	0.000351	CcSEcCtD
Procainamide—Nausea—Docetaxel—breast cancer	3.83e-05	0.000351	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—breast cancer	3.83e-05	0.000351	CcSEcCtD
Procainamide—Gastrointestinal pain—Methotrexate—breast cancer	3.8e-05	0.000348	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—breast cancer	3.78e-05	0.000346	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—breast cancer	3.76e-05	0.000344	CcSEcCtD
Procainamide—Probenecid—CYP3A4—breast cancer	3.73e-05	0.00728	CrCbGaD
Procainamide—Nausea—Capecitabine—breast cancer	3.71e-05	0.000339	CcSEcCtD
Procainamide—Urticaria—Methotrexate—breast cancer	3.69e-05	0.000338	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—breast cancer	3.68e-05	0.000336	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—breast cancer	3.68e-05	0.000336	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.67e-05	0.000336	CcSEcCtD
Procainamide—Benzocaine—ABCB1—breast cancer	3.67e-05	0.00715	CrCbGaD
Procainamide—Lidocaine—CYP3A4—breast cancer	3.59e-05	0.007	CrCbGaD
Procainamide—Feeling abnormal—Epirubicin—breast cancer	3.59e-05	0.000328	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—breast cancer	3.56e-05	0.000326	CcSEcCtD
Procainamide—Decreased appetite—Doxorubicin—breast cancer	3.5e-05	0.00032	CcSEcCtD
Procainamide—Urticaria—Epirubicin—breast cancer	3.46e-05	0.000316	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—breast cancer	3.44e-05	0.000315	CcSEcCtD
Procainamide—Abdominal pain—Epirubicin—breast cancer	3.44e-05	0.000315	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—breast cancer	3.43e-05	0.000313	CcSEcCtD
Procainamide—Asthenia—Methotrexate—breast cancer	3.34e-05	0.000305	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—breast cancer	3.32e-05	0.000304	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—breast cancer	3.29e-05	0.000301	CcSEcCtD
Procainamide—Pruritus—Methotrexate—breast cancer	3.29e-05	0.000301	CcSEcCtD
Procainamide—Probenecid—ALB—breast cancer	3.26e-05	0.00635	CrCbGaD
Procainamide—Hypersensitivity—Epirubicin—breast cancer	3.21e-05	0.000293	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—breast cancer	3.2e-05	0.000293	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—breast cancer	3.18e-05	0.000291	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—breast cancer	3.18e-05	0.000291	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—breast cancer	3.18e-05	0.000291	CcSEcCtD
Procainamide—Asthenia—Epirubicin—breast cancer	3.12e-05	0.000286	CcSEcCtD
Procainamide—Probenecid—ABCB1—breast cancer	3.11e-05	0.00606	CrCbGaD
Procainamide—Pruritus—Epirubicin—breast cancer	3.08e-05	0.000282	CcSEcCtD
Procainamide—Dizziness—Methotrexate—breast cancer	3.07e-05	0.000281	CcSEcCtD
Procainamide—Aminohippurate—ABCB1—breast cancer	3.07e-05	0.00598	CrCbGaD
Procainamide—Lidocaine—ABCB1—breast cancer	2.99e-05	0.00583	CrCbGaD
Procainamide—Diarrhoea—Epirubicin—breast cancer	2.98e-05	0.000272	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—breast cancer	2.97e-05	0.000271	CcSEcCtD
Procainamide—Vomiting—Methotrexate—breast cancer	2.96e-05	0.000271	CcSEcCtD
Procainamide—Sunitinib—CYP3A4—breast cancer	2.94e-05	0.00573	CrCbGaD
Procainamide—Asthenia—Doxorubicin—breast cancer	2.89e-05	0.000264	CcSEcCtD
Procainamide—Dizziness—Epirubicin—breast cancer	2.88e-05	0.000263	CcSEcCtD
Procainamide—Pruritus—Doxorubicin—breast cancer	2.85e-05	0.000261	CcSEcCtD
Procainamide—Vomiting—Epirubicin—breast cancer	2.77e-05	0.000253	CcSEcCtD
Procainamide—Nausea—Methotrexate—breast cancer	2.76e-05	0.000253	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—breast cancer	2.75e-05	0.000252	CcSEcCtD
Procainamide—Dizziness—Doxorubicin—breast cancer	2.66e-05	0.000244	CcSEcCtD
Procainamide—Nausea—Epirubicin—breast cancer	2.58e-05	0.000237	CcSEcCtD
Procainamide—Vomiting—Doxorubicin—breast cancer	2.56e-05	0.000234	CcSEcCtD
Procainamide—Sunitinib—ABCB1—breast cancer	2.45e-05	0.00477	CrCbGaD
Procainamide—Nausea—Doxorubicin—breast cancer	2.39e-05	0.000219	CcSEcCtD
Procainamide—CYP2D6—Metabolism—GSTA2—breast cancer	3.09e-06	2.87e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTP1—breast cancer	3.07e-06	2.86e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GPX4—breast cancer	3.05e-06	2.83e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SULT1A1—breast cancer	3.05e-06	2.83e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—HMOX1—breast cancer	3.03e-06	2.82e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GPX1—breast cancer	3.03e-06	2.81e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ITPR1—breast cancer	3.03e-06	2.81e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CYP1A1—breast cancer	3e-06	2.79e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EDNRB—breast cancer	2.99e-06	2.78e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—IDH1—breast cancer	2.98e-06	2.77e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTA1—breast cancer	2.98e-06	2.77e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ERCC2—breast cancer	2.97e-06	2.76e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PGR—breast cancer	2.96e-06	2.75e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—THBS1—breast cancer	2.95e-06	2.74e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NAT2—breast cancer	2.94e-06	2.74e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CD—breast cancer	2.94e-06	2.73e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ABCB1—breast cancer	2.91e-06	2.7e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ALB—breast cancer	2.9e-06	2.7e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CAV1—breast cancer	2.89e-06	2.68e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—COMT—breast cancer	2.88e-06	2.67e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTP1—breast cancer	2.87e-06	2.66e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TYMS—breast cancer	2.86e-06	2.65e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—HMOX1—breast cancer	2.83e-06	2.62e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NCOR1—breast cancer	2.83e-06	2.62e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTM1—breast cancer	2.83e-06	2.62e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PLA2G4A—breast cancer	2.83e-06	2.62e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ITPR1—breast cancer	2.82e-06	2.62e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FLT1—breast cancer	2.81e-06	2.61e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGF3—breast cancer	2.8e-06	2.6e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SQSTM1—breast cancer	2.8e-06	2.6e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—MTHFR—breast cancer	2.8e-06	2.6e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CG—breast cancer	2.79e-06	2.59e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—NOS3—breast cancer	2.78e-06	2.58e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JAG1—breast cancer	2.77e-06	2.57e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.76e-06	2.56e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOTCH3—breast cancer	2.75e-06	2.56e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PARP1—breast cancer	2.75e-06	2.56e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CALCA—breast cancer	2.72e-06	2.53e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ABCB1—breast cancer	2.71e-06	2.52e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GPX1—breast cancer	2.71e-06	2.51e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RPS6—breast cancer	2.69e-06	2.5e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CYP1A1—breast cancer	2.68e-06	2.49e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGF4—breast cancer	2.67e-06	2.48e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TYMS—breast cancer	2.66e-06	2.47e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCR4—breast cancer	2.66e-06	2.47e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCL12—breast cancer	2.66e-06	2.47e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ERCC2—breast cancer	2.66e-06	2.47e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTM1—breast cancer	2.63e-06	2.45e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PLA2G4A—breast cancer	2.63e-06	2.45e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NCOR1—breast cancer	2.63e-06	2.45e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CG—breast cancer	2.63e-06	2.45e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PAK1—breast cancer	2.61e-06	2.42e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MED12—breast cancer	2.58e-06	2.4e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—DPYD—breast cancer	2.58e-06	2.4e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CAV1—breast cancer	2.58e-06	2.4e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CB—breast cancer	2.56e-06	2.38e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TCF7L2—breast cancer	2.56e-06	2.38e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AKT2—breast cancer	2.55e-06	2.37e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ALDOA—breast cancer	2.54e-06	2.36e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—breast cancer	2.54e-06	2.36e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CG—breast cancer	2.53e-06	2.35e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GPX1—breast cancer	2.52e-06	2.34e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—MTHFR—breast cancer	2.5e-06	2.32e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CYP1A1—breast cancer	2.5e-06	2.32e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ERCC2—breast cancer	2.48e-06	2.3e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HSP90AA1—breast cancer	2.47e-06	2.29e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOTCH2—breast cancer	2.47e-06	2.29e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOA3—breast cancer	2.47e-06	2.29e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.46e-06	2.29e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CD—breast cancer	2.45e-06	2.28e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC2A2—breast cancer	2.45e-06	2.28e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PRL—breast cancer	2.4e-06	2.23e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AGTR1—breast cancer	2.4e-06	2.23e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CPT1A—breast cancer	2.4e-06	2.23e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MTR—breast cancer	2.4e-06	2.23e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ABCG2—breast cancer	2.4e-06	2.23e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ADAM10—breast cancer	2.37e-06	2.2e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STK11—breast cancer	2.37e-06	2.2e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HPGDS—breast cancer	2.35e-06	2.19e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CG—breast cancer	2.35e-06	2.18e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PLG—breast cancer	2.34e-06	2.18e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HBA1—breast cancer	2.34e-06	2.17e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—MTHFR—breast cancer	2.33e-06	2.16e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AKT2—breast cancer	2.32e-06	2.15e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CD—breast cancer	2.31e-06	2.15e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGF10—breast cancer	2.3e-06	2.14e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CAV1—breast cancer	2.3e-06	2.14e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ALB—breast cancer	2.28e-06	2.12e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTT1—breast cancer	2.28e-06	2.12e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ACHE—breast cancer	2.28e-06	2.12e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CD—breast cancer	2.23e-06	2.07e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PDGFA—breast cancer	2.22e-06	2.07e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTEN—breast cancer	2.21e-06	2.06e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TGFBR2—breast cancer	2.19e-06	2.04e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NOS3—breast cancer	2.19e-06	2.03e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP17A1—breast cancer	2.16e-06	2.01e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ITPR1—breast cancer	2.16e-06	2e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CAV1—breast cancer	2.15e-06	1.99e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT5A—breast cancer	2.14e-06	1.99e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ERBB4—breast cancer	2.14e-06	1.99e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP3—breast cancer	2.14e-06	1.99e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ENO1—breast cancer	2.14e-06	1.99e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS1—breast cancer	2.14e-06	1.99e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CB—breast cancer	2.14e-06	1.98e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CG—breast cancer	2.1e-06	1.95e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SMAD4—breast cancer	2.07e-06	1.93e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CD—breast cancer	2.06e-06	1.92e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IGF1R—breast cancer	2.06e-06	1.92e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOA2—breast cancer	2.06e-06	1.91e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CXCL8—breast cancer	2.05e-06	1.91e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ALB—breast cancer	2.04e-06	1.89e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HES1—breast cancer	2.03e-06	1.88e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CB—breast cancer	2.02e-06	1.87e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NCOR1—breast cancer	2.01e-06	1.87e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PLA2G4A—breast cancer	2.01e-06	1.87e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—breast cancer	2e-06	1.86e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—FASN—breast cancer	2e-06	1.86e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CSF2—breast cancer	1.99e-06	1.85e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGF1—breast cancer	1.99e-06	1.85e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—BCHE—breast cancer	1.99e-06	1.85e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—RAF1—breast cancer	1.99e-06	1.85e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRG1—breast cancer	1.98e-06	1.84e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC5A5—breast cancer	1.96e-06	1.82e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—H2AFX—breast cancer	1.96e-06	1.82e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL2—breast cancer	1.96e-06	1.82e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CG—breast cancer	1.96e-06	1.82e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NOS3—breast cancer	1.95e-06	1.81e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—E2F1—breast cancer	1.95e-06	1.81e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CB—breast cancer	1.94e-06	1.8e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NQO1—breast cancer	1.9e-06	1.76e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC2A1—breast cancer	1.9e-06	1.76e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SPP1—breast cancer	1.87e-06	1.74e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CXCL8—breast cancer	1.86e-06	1.73e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ERBB3—breast cancer	1.85e-06	1.72e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP3A4—breast cancer	1.85e-06	1.72e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGFR2—breast cancer	1.85e-06	1.72e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CD—breast cancer	1.84e-06	1.71e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ALB—breast cancer	1.82e-06	1.69e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP1B1—breast cancer	1.82e-06	1.69e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CB—breast cancer	1.8e-06	1.67e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HSP90AA1—breast cancer	1.78e-06	1.66e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—breast cancer	1.78e-06	1.66e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL2—breast cancer	1.78e-06	1.65e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TERT—breast cancer	1.78e-06	1.65e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTEN—breast cancer	1.74e-06	1.62e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NOS3—breast cancer	1.74e-06	1.62e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOA1—breast cancer	1.74e-06	1.61e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGFR1—breast cancer	1.72e-06	1.6e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CD—breast cancer	1.72e-06	1.6e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—STK11—breast cancer	1.71e-06	1.59e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP19A1—breast cancer	1.71e-06	1.59e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HIF1A—breast cancer	1.7e-06	1.58e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ALB—breast cancer	1.7e-06	1.58e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—LEP—breast cancer	1.66e-06	1.54e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CAV1—breast cancer	1.64e-06	1.53e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KDR—breast cancer	1.62e-06	1.51e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NOS3—breast cancer	1.62e-06	1.51e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CB—breast cancer	1.61e-06	1.49e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—breast cancer	1.59e-06	1.48e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—COMT—breast cancer	1.59e-06	1.48e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTP1—breast cancer	1.58e-06	1.47e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ESR1—breast cancer	1.58e-06	1.47e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FN1—breast cancer	1.56e-06	1.45e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CA—breast cancer	1.56e-06	1.45e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HMOX1—breast cancer	1.56e-06	1.45e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ITPR1—breast cancer	1.56e-06	1.45e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTEN—breast cancer	1.56e-06	1.44e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NFKBIA—breast cancer	1.54e-06	1.43e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOTCH1—breast cancer	1.53e-06	1.42e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CB—breast cancer	1.5e-06	1.39e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ABCB1—breast cancer	1.5e-06	1.39e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—APC—breast cancer	1.5e-06	1.39e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CG—breast cancer	1.5e-06	1.39e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KIT—breast cancer	1.5e-06	1.39e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—breast cancer	1.48e-06	1.38e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EGF—breast cancer	1.48e-06	1.37e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TYMS—breast cancer	1.47e-06	1.37e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.45e-06	1.35e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOR1—breast cancer	1.45e-06	1.35e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTM1—breast cancer	1.45e-06	1.35e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—MAPK3—breast cancer	1.43e-06	1.33e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—BRAF—breast cancer	1.41e-06	1.31e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GPX1—breast cancer	1.39e-06	1.29e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTEN—breast cancer	1.39e-06	1.29e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP1A1—breast cancer	1.38e-06	1.28e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IGF1—breast cancer	1.37e-06	1.27e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AKT2—breast cancer	1.37e-06	1.27e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ERCC2—breast cancer	1.37e-06	1.27e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—EGFR—breast cancer	1.36e-06	1.27e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CD—breast cancer	1.31e-06	1.22e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	1.3e-06	1.21e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SERPINE1—breast cancer	1.3e-06	1.21e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTEN—breast cancer	1.29e-06	1.2e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KRAS—breast cancer	1.29e-06	1.2e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MTHFR—breast cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—AKT1—breast cancer	1.28e-06	1.19e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOS3—breast cancer	1.24e-06	1.15e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CA—breast cancer	1.23e-06	1.14e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CAV1—breast cancer	1.19e-06	1.1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	1.18e-06	1.1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MDM2—breast cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RAF1—breast cancer	1.17e-06	1.09e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RELA—breast cancer	1.17e-06	1.09e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ERBB2—breast cancer	1.16e-06	1.08e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CB—breast cancer	1.15e-06	1.06e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MTOR—breast cancer	1.15e-06	1.06e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCL8—breast cancer	1.1e-06	1.02e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CA—breast cancer	1.1e-06	1.02e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—breast cancer	1.09e-06	1.02e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CG—breast cancer	1.08e-06	1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDKN1B—breast cancer	1.08e-06	9.99e-06	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AKT1—breast cancer	1.06e-06	9.88e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CASP3—breast cancer	1.05e-06	9.79e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL2—breast cancer	1.05e-06	9.78e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL6—breast cancer	1.05e-06	9.73e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCND1—breast cancer	1.03e-06	9.53e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JUN—breast cancer	1.02e-06	9.51e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CTNNB1—breast cancer	1.02e-06	9.44e-06	CbGpPWpGaD
Procainamide—ACHE—Metabolism—AKT1—breast cancer	1e-06	9.33e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP9—breast cancer	9.96e-07	9.25e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDKN1A—breast cancer	9.93e-07	9.22e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTEN—breast cancer	9.9e-07	9.2e-06	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CA—breast cancer	9.8e-07	9.1e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK8—breast cancer	9.69e-07	9e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AKT1—breast cancer	9.66e-07	8.97e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CD—breast cancer	9.49e-07	8.82e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ALB—breast cancer	9.37e-07	8.7e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SRC—breast cancer	9.18e-07	8.53e-06	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CA—breast cancer	9.13e-07	8.48e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NOS3—breast cancer	8.97e-07	8.33e-06	CbGpPWpGaD
Procainamide—BCHE—Metabolism—AKT1—breast cancer	8.96e-07	8.32e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VEGFA—breast cancer	8.94e-07	8.31e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT3—breast cancer	8.86e-07	8.23e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK3—breast cancer	8.46e-07	7.86e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CB—breast cancer	8.28e-07	7.69e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MYC—breast cancer	8.23e-07	7.64e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TGFB1—breast cancer	8.21e-07	7.63e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—breast cancer	8.2e-07	7.62e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EGFR—breast cancer	8.05e-07	7.48e-06	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—AKT1—breast cancer	8.01e-07	7.44e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KRAS—breast cancer	7.6e-07	7.06e-06	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—AKT1—breast cancer	7.46e-07	6.93e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTEN—breast cancer	7.15e-07	6.64e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CA—breast cancer	6.99e-07	6.49e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—breast cancer	6.76e-07	6.28e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—breast cancer	6.46e-07	6e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL6—breast cancer	6.19e-07	5.75e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AKT1—breast cancer	5.71e-07	5.3e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CA—breast cancer	5.04e-07	4.69e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—AKT1—breast cancer	4.12e-07	3.83e-06	CbGpPWpGaD
